A Heat-Stable Hepatitis B Vaccine Formulation

This article, published in Human Vaccines (Human Vaccines 5:8, 1-7; August 2009), details a collaborative effort between PATH, Arecor, and the University of Colorado Denver School of Pharmacy that has resulted in a new formulation for recombinant hepatitis B vaccine that demonstrates improved stability at elevated temperatures. The formulation exhibited 9-week stability at 55°C and was also shown to be stable at both 37°C and 45°C for at least six months. This new vaccine formulation has the potential to be stored at room temperature for part of its shelf life and will help ensure the potency of the vaccine in areas where the cold chain is insufficient.

Publication date: August 2009

A Heat-Stable Hepatitis B Vaccine Formulation

206.4 KB PDF
View Resource